Previous article![]( "Top 25 Indian Pharma Companies by Revenues in 2024")
Next article![]( "India’s Medical Devices Market: Strategic Implications and Key Investors")
Monday, February 16, 2026
28
C
Bengaluru
Hot topics
Digital Darwinism or Digital Expert – The Choice for Indian Pharma is Clear
It is heartening to see that Pharma marketers have...
The Rise and Fall of A.H. Robins Company: A Tale of Innovation Marred by One Acquisition
A.H. Robins Company was a formidable name in the...
Who Is Monitoring Quality in India’s Small Drug Units?
The Telangana Drugs Control Administration’s stop-use notice on a...
Pharma GCCs – What Used to Happen in Boston or Basel Now Happens in Bangalore
GCCs - Indian Pharma moves up the Value Chain...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Hot topics
AI and the Future of Pharma Field Sales: Boon or Bane?
India’s pharmaceutical industry runs on the strength of its...
Patient Centered Pharma – Pipe Dream or Possible?
To me, patient centricity is as fascinating a concept as it is contradictory. It is fascinating because it puts power into the hands of the patient. And it is contradictory because pharma does not like giving away power over its messages or processes. Pharma has traditionally never enjoyed interaction and has depended on ‘pushing’ messages across rather than having ‘conversations’. It probably also explains why we make do with medical reps who are not the sharpest knives in the drawer and scarcely invest in sharpening them.
The Semaglutide Story: How One Molecule Re‑wired Obesity, Patents and Pharma Profits
1. From Gut Hormone to “Wonder Drug”
If you strip...
Dr. Peter Velev, CEO of CredoWeb discussing Digital in Pharma with MedicinMan
The digital revolution is the fourth industrial revolution. It changes models, processes and whole public sectors. In many reports you will find that, in terms of digitalization, pharma is just next to the public sector, as least digitalized. Pharma just started late. There are many reasons for that – it is one of the most regulated industries with lots of sensitive data involved and many ethical aspects. But the slowed down digitalization has a lot to do with some subjective reasons. Adopting digital technologies requires changing existing models which requires a different mindset – and this is difficult to achieve. Nowadays, in the situation of a global pandemic, we see that digital communication is not only necessary to be successful but it is a must in order to adapt to the New Normality.
Rx 2024 – Top 25 Drugs by Sales, Growth & Market Trends
The pharmaceutical market in 2024 saw major shifts driven...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Newsletter
Get important news delivered directly to your inbox and stay connected!